This Is Like Getting the Chance to Buy Apple and IBM When They Were Newly Public

By Patrick CoxPosted September 30, 2008

I was just talking to a trusted friend and source, economist and ex-professional musician, Jeff Scot. Scot has been warning for a long time that the big subprime-burdened banks were at risk.

You Must Be A Subscriber To View This Content.

If you are already a subscriber, click the login button below to get access. Not yet a subscriber? Checkout our publication below and get access today!

Breakthrough Technology Alert

This is the best time to be investing in world-changing technologies, as unprecedented innovations are taking off right now… Breakthrough Technology Alert tirelessly researches these exciting new breakthrough technologies to keep you well informed, outline specific opportunities, and keep you ahead of the game.

Patrick Cox

Patrick Cox has lived deep inside transformative technologies for over 25 years. In the 1980s, he worked in software development and manufacturing. By the mid-‘90s, he consulted for Netscape–which handled 90% of all Internet browsing traffic at the time. InfoWorld and USA Today have featured his research, and he’s written for The Wall Street Journal,...

View More By Patrick Cox

Glaxo Kills Resveratrol Stock Promise, but Not Life Extension Possibilities

By Patrick CoxPosted April 29, 2008

Several months ago, I wrote to you about Sirtris Pharmaceuticals, the company working with molecules related to resveratrol.

Huge Wins as BioTime Wins Geron IP and Star Scientific Thyroiditis Data Published

By Patrick CoxPosted January 8, 2013

I hope you've had a pleasant holiday season. As this is the first alert of the new year, I'd like to talk about the two biggest developments of 2012. Coincidentally, both culminated in the last few days, which has me both very tired and very excited. I suspect, by the way, that these two developments will maintain their ranking for years to come. They are BioTime's just-announced acquisition of Geron's massive stem cell patent library and the preliminary data from the Johns Hopkins thyroiditis study using Star Scientific's) nutraceutical anatabine citrate.

Historic Breakthroughs Will Change the World and Create Fortunes

By Patrick CoxPosted May 7, 2013

Three announcements from world scientific research last week will be felt for years to come, creating fortunes in the process. A new study has brought unexpected and powerful validation of Star Scientific's life-extending nutraceutical. Also in the natural products arena, ChromaDex appears to be the star of an upcoming session of the Federation of American Societies for Experimental Biology. We'll start, however, with important BioTime news and a newly discovered hormone that could give normal lives to millions of diabetics.

Combatting The World’s Deadliest Disease

By Ray BlancoPosted March 18, 2019

Things have been busy with some of our recommendations recently. Ray gives updates on a few companies in the Breakthrough Technology portfolio. Plus, information in lifesaving gold…

Stem Cell Ruling Not So Bad for Business, Not So Good for America

By Patrick CoxPosted August 31, 2010

As you probably know, District Court Judge Royce Lamberth has enjoined federal funding of human embryonic stem cell (hESC) research. I wasn't going to write about this, for the simple reason that it will have minimal impact on our companies. Nevertheless, let's take a look...

Excellent News From Our Biotech Companies

By Ray BlancoPosted October 8, 2013

One of our pharmaceutical companies has unveiled further data from its completed Phase 2 trial in melanoma at the European Cancer Congress 2013. If you recall, this company’s cancer compound, PV-10, is derived from a rose-colored chemical dye first synthesized in 1882.